1.
Med Hypotheses
; 160: 110774, 2022 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35095174
RESUMO
Diethylcarbamazine, the antiparasitic drug, also possesses anti-inflammatory and immunomodulatory activities. The anti-fibrotic activity of diethylcarbamazine makes it a potential candidate to treat coronavirus disease 2019 (COVID-19)-related pulmonary fibrosis. Experimental and clinical studies should assess this possible effect.